Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from D.Western Therapeutics Institute ( (JP:4576) ).
D. Western Therapeutics Institute, Inc. has received FDA approval for its new product, Bondlido, a lidocaine patch developed with MEDRx for treating post-herpetic neuralgia in adults. The product is expected to launch in the US in the first half of 2026, potentially improving the company’s earnings over the medium to long term by offering a superior alternative to existing products in the $162 million US lidocaine patch market.
The most recent analyst rating on (JP:4576) stock is a Sell with a Yen102.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.
More about D.Western Therapeutics Institute
D. Western Therapeutics Institute, Inc. operates in the pharmaceutical industry, focusing on the development of therapeutic products. The company is known for its innovative approaches in drug development, particularly in collaboration with other firms, such as MEDRx, to enhance treatment options in the market.
Average Trading Volume: 1,156,304
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.43B
For an in-depth examination of 4576 stock, go to TipRanks’ Overview page.